Update on the use of deferasirox in the management of iron overload
Update on the use of deferasirox in the management of iron overload
复制标题
地拉罗司治疗铁过载的最新进展
DOI：
--
复制
发表时间：
2009
影响因子：
2.8
通讯作者：
M. Cappellini
中科院分区：
文献类型：
--
作者：
A. Taher;M. Cappellini
Regular blood transfusions as supportive care for patients with chronic anemia inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload cause significant morbidity and mortality if not effectively treated with chelation therapy. Based on a comprehensive clinical development program, the once-daily, oral iron chelator deferasirox (Exjade®) is approved for the treatment of transfusional iron overload in adult and pediatric patients with various transfusion-dependent anemias, including β-thalassemia and the myelodysplastic syndromes. Deferasirox dose should be titrated for each individual patient based on transfusional iron intake, current iron burden and whether the goal is to decrease or maintain body iron levels. Doses of >30 mg/kg/day have been shown to be effective with a safety profile consistent with that observed at doses <30 mg/kg/day. Recent data have highlighted the ability of deferasirox to decrease cardiac iron levels and to prevent the accumulation of iron in the heart. The long-term efficacy and safety of deferasirox for up to 5 years of treatment have now been established. The availability of this effective and generally well tolerated oral therapy represents a significant advance in the management of transfusional iron overload.
影响因子：
20.3
作者：
P. Pootrakul;K. Kitcharoen;P. Yansukon;P. Wasi;S. Fucharoen;P. Charoenlarp;G. Brittenham;M. Pippard;C. Finch
通讯作者：
P. Pootrakul;K. Kitcharoen;P. Yansukon;P. Wasi;S. Fucharoen;P. Charoenlarp;G. Brittenham;M. Pippard;C. Finch
影响因子：
158.5
作者：
BRITTENHAM, GM;GRIFFITH, PM;HARRIS, JW
通讯作者：
HARRIS, JW